Experienced in Osteomyelitis

Anne S. Kubasch

Dresden, SN, DE 
Experienced in Osteomyelitis
Dresden, SN, DE 
OverviewLocationsClinical Research

Overview

Anne Kubasch practices in Dresden, Germany. Ms. Kubasch is rated as an Experienced expert by MediFind in the treatment of Osteomyelitis. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Chronic Recurrent Multifocal Osteomyelitis, and Splenectomy.

Her clinical research consists of co-authoring 38 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Osteomyelitis.

Gender
Female

Locations

Dresden, SN, Germany
Other Locations
Leipzig, SN, Germany
Friedrichshain Bezirk, BE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase IIIb, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Luspatercept in Patients With Lower-risk MDS and Ring-sideroblastic Phenotype (MDS-RS)
A Phase IIIb, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Luspatercept in Patients With Lower-risk MDS and Ring-sideroblastic Phenotype (MDS-RS)
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug
Study Drug: Luspatercept
Study Phase: Phase 3
A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients With IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or MDS/MPN
A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients With IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or MDS/MPN
Enrollment Status: Terminated
Publish Date: May 06, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 2
View 1 Less Clinical Trial

38 Total Publications

IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score.
IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score.
Journal: Blood
Published: November 04, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kubasch's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile